Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis

Brain

Volumn 128, Issue 2, 2005, Pages 375-385

  Diem, Ricarda ^a   Sättler, Muriel B ^a   Merkler, Doron ^b   Demmer, Iris ^a   Maier, Katharina ^a   Stadelmann, Christine ^b   Ehrenreich, Hannelore ^c   Bähr, Mathias ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b Institut fur Neuropathologie   (Germany)

^c MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

Author keywords

Erythropoietin; Experimental autoimmune encephalomyelitis; Methylprednisolone; Neuroprotection; Visual evoked potentials

Indexed keywords

ERYTHROPOIETIN; METHYLPREDNISOLONE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DRUG EFFICACY; ELECTRORETINOGRAM; EVOKED VISUAL RESPONSE; FEMALE; MONOTHERAPY; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVE FIBER; NEUROPROTECTION; NONHUMAN; OPTIC NERVE; OPTIC NERVE DISEASE; PRIORITY JOURNAL; RAT; RETINA GANGLION CELL;

ANIMALS; DRUG THERAPY, COMBINATION; ELECTRORETINOGRAPHY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ERYTHROPOIETIN, RECOMBINANT; EVOKED POTENTIALS, VISUAL; FEMALE; METHYLPREDNISOLONE; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; OPTIC NERVE; OPTIC NEURITIS; RATS; RATS, INBRED BN; RETINAL GANGLION CELLS; SIGNAL TRANSDUCTION;

EID: 13544269276     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awh365     Document Type: Article

References (40)

1. Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines ML, et al. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 2002; 952: 128-34.
2. Barnabe-Heider F, Miller FD. Endogenously produced neurotrophins regulate survival and differentiation of cortical progenitors via distinct signaling pathways. J Neurosci 2003; 23: 5149-60.
3. Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 1999; 19: 643-51.
4. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000; 97: 10526-31.
5. Brück W, Bitsch A, Kolenda H, Brück Y, Stiefel M, Lassmann, H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997; 42: 783-93.
6. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Young VW. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002; 125: 1297-308.
7. Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 2000; 247: 435-42.
8. Darman J, Backovic S, Dike S, Maragakis NJ, Krishnan C, Rothstein JD et al. Viral-induced spinal motor neuron death is non-cell-autonomous and involves glutamate excitotoxicity. J Neurosci 2004; 24: 7566-75.
9. De Stefano N, Guidi L, Stromillo ML, Bartolozzi ML, Federico A. Imaging neuronal and axonal degeneration in multiple sclerosis. Neurol Sci Suppl 2003a; 5: 283-6.
10. De Stefano N, Matthews PM, Filippi M, Agosta F, De Luca M, Bartolozzi ML, et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003b; 60: 1157-62.
11. Diem R, Meyer R, Weishaupt JH, Bähr M. Reduction of potassium currents and phosphatidylinositol 3-kinase-dependent Akt phosphorylation by tumor necrosis factor-α rescues axotomized retinal ganglion cells from retrograde cell death in vivo. J Neurosci 2001; 21: 2058-66.
12. Diem R, Hobom M, Maier K, Weissert R, Storch MK, Meyer R, et al. Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway. J Neurosci 2003; 23: 6993-7000.
13. Hammarberg H, Lidman O, Lundberg C, Eltayeb SY, Gielen AW, Muhallab S, et al. Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J Neurosci 2000; 20: 5283-91.
14. Hickman SJ, Kapoor R, Jones SJ, Altmann DR, Plant GT, Miller DH. Corticosteroids do not prevent optic nerve atrophy following optic neuritis. J Neurol Neurosurg Psychiatry 2003; 74: 1139-41.
15. Hobom M, Storch MK, Weissert R, Maier K, Radhakrishnan A, Kramer B, et al. Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis. Brain Pathol 2004; 14: 148-57.
16. Hood DC, Greenstein VC. Multifocal VEP and ganglion cell damage: applications and limitations for the study of glaucoma. Prog Retin Eye Res 2003; 22: 201-51.
17. Isenmann S, Wahl C, Krajewski S, Reed JC, Bahr M. Up-regulation of Bax protein in degenerating retinal ganglion cells precedes apoptotic cell death after optic nerve lesion in the rat. Eur J Neurosci 1997; 9: 1763-72.
18. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 1992; 72: 449-89.
19. Kanwar JR, Kanwar RK, Krissansen GW. Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis. Brain 2004; 127: 1313-31.
20. Kermer P, Klöcker N, Bähr M. Long-term effect of inhibition of ced 3-like caspases on the survival of axotomized retinal ganglion cells in vivo. Exp Neurol 1999; 158: 202-5.
21. Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WE, et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 1999; 189: 865-70.
22. Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, Olsson T, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000; 157: 267-76.
23. Kriz J, Nguyen MD, Julien JP. Minocyline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002; 10: 268-78.
24. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, et al. Derivates of erythropoietin that are tissue protective but not erythropoietic. Science 2004; 239-42.
25. Losseff NA, Wang L, Lai HM, Yoo DS, Gawne-Cain ML, McDonald WI, et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996; 119: 2009-19.
26. Meyer R, Weissert R, Diem R, Storch MK, de Graaf KL, Kramer B, et al. Acute neuronal apoptosis in a rat model of multiple sclerosis. J Neurosci 2001; 21: 6214-20.
27. Noseworthy JH, Gold R, Hartung HP. Treatment of multiple sclerosis: recent trials and future perspectives. Curr Opin Neurol 1999; 12: 279-93.
28. Okuda Y, Sakoda S, Fujimura H, Saeki Y, Kishimoto T, Yanagihara T. IL-6 plays a crucial role in the induction phase of myelin oligodendrocyte glucoprotein 35-55 induced experimental autoimmune encephalomyelitis. J Neuroimmunol 1999; 101: 188-96.
29. Parry A, Corkill R, Blamire AM, Palace J, Narayanan S, Arnold D, et al. Beta-interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. J Neurol 2003; 250: 171-8.
30. Peterson JW, Bö L, Mörk S, Chang A, Trapp BD. Transected neuntes, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001; 50: 389-400.
31. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000; 6: 67-70.
32. Probert L, Eugster HP, Akassoglou K, Bauer J, Frei K, Lassmann H, et al. TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease. Brain 2000; 123: 2005-19.
33. Sättler MB, Merkler D, Maier K, Stadelmann C, Ehrenreich H, Bähr M, et al. Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death Differ 2004; 11 (Suppl 2); S181-92.
34. Smith T, Groom A, Zhu B, Turski L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 2000; 6: 62-6.
35. Storch MK, Stefferl A, Brehm U, Weissert R, Wallstrom E, Kerschensteiner M, et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 1998; 8: 681-94.
36. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-86.
37. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999; 12: 295-302.
38. Weissert R, Wallstrom E, Storch MK, Stefferl A, Lorentzen J, Lassmann H, et al. MHC haplotype-dependent regulation of MOG-induced EAE in rats. J Clin Invest 1998; 102: 1265-73.
39. Wekerle H, Kojima K, Lannes-Vieira J, Lassmann H, Linington, C. Animal models. Ann Neurol Suppl 1994; 36: S47-53.
40. Yamada M, Tanabe K, Wada K, Shimoke K, Ishikawa Y, Ikeuchi T, et al. Differences in survival-promoting effects and intracellular signaling properties of BDNF and IGF-1 in cultured cerebral cortical neurons. J Neurochem 2001; 78: 940-51.